

Normal platelet function in platelet concentrates requires non-platelet cells: a comparative in vitro evaluation of leucocyte-rich (type 1a) and leucocyte-poor (type 3b) platelet concentrates

[William R Parrish](#),¹ [Breana Roides](#),¹ [Julia Hwang](#),¹ [Michael Mafilios](#),² [Brooks Story](#),¹ and [Samir Bhattacharyya](#)¹

[Author information](#) ► [Article notes](#) ► [Copyright and License information](#) ► [Disclaimer](#)

This article has been [cited by](#) other articles in PMC.

Conclusions

What are the new findings?

- Compared with whole blood, leucocyte-poor platelet-rich plasma (PRP) contains <1% and 20% of red blood cells and white blood cells, respectively, and it is deficient in coagulation, clot retraction and platelet growth factor release when reactivated with CaCl₂.
- Platelet releasate (serum) from reactivated leucocyte-poor PRP containing greater than twofold increased platelet concentration does not stimulate greater tendon cell proliferation than whole blood serum in vitro.
- Exogenous thrombin addition rescues coagulation and clot retraction deficits and significantly improves platelet growth factor release in leucocyte-poor PRP.
- This study demonstrates that non-platelet cellular components in platelet concentrates are important for proper platelet function, including thrombin generation, clot retraction and growth factor release.

Introduction

Platelet-rich plasma (PRP) is an autologous, biologically active derivative of whole blood that contains therapeutic platelet concentrations elevated at least fivefold above baseline.¹ By concentrating platelets into PRP, a large reservoir of autologous growth factors is generated, which if administered appropriately can establish an optimal environment for accelerated healing, including the reduction of pain and resolution of inflammation.²⁻⁷ There are currently more than 2 dozen commercially available systems in the worldwide market that concentrate whole blood into a platelet-rich substance. These various devices and techniques have resulted in a wide range of PRP final products that can vary greatly, especially in the concentration of platelets and the inclusion or exclusion of leucocytes and red blood cells (RBCs). A current area of debate is how non-platelet components of whole blood contribute to the biological activity of PRP.⁸⁻¹⁴ In particular, some authors have suggested based on preclinical studies that RBCs and white blood cells (WBCs) may be detrimental as these cells may participate in inflammatory reactions that can lead to damage in the treated tissue.¹⁴⁻¹⁶ Although these concerns remain unsubstantiated in the clinical literature,^{9, 13} an important question that does remain is whether non-platelet cellular components of PRP contribute to its biological activity in a manner that may impact platelet activation and growth factor release, and thus the therapeutic utility of the PRP.

In the context of whole blood, the intimate and dynamic interactions between platelets and other cells is crucial for providing the physiological mechanisms that prevent infection and promote healing in the event of an injury. For example, collagen-activated platelets are known to stimulate RBCs to activate robust prothrombin conversion.^{12, 17-20} This RBC-dependent amplification mechanism generates sufficient thrombin to convert the forming platelet plug into a fibrin clot and ensures appropriate levels of reciprocal platelet activation and growth factor release that are proportional to the injury.²⁰ Equally important are interactions between platelets and

leucocytes that coordinate the inflammatory and immune responses to match the antimicrobial and repair needs of the damaged tissue.^{11 17 20-28} These coordinated activities control the level of inflammation caused by platelet activation and ultimately trigger the healing cascade, which results in the restoration of the damaged tissue to a healthy state.^{2 4 5 7 29} Therefore, similar intercellular platelet interactions that are foundational in normal wound repair might also function to influence the bioactivity of platelets in PRP. To investigate this hypothesis, we evaluated two commercially available PRP preparation systems, the Arthrex Autologous Conditioned Plasma (ACP) dual syringe system and the Mitek Sports Medicine PEAK PRP system, that generate platelet concentrates on each end of the spectrum of PRP ([table 1](#)).⁵

Table 1

Platelet-rich plasma classification system⁵

Type	White blood cells	Activated?
1	Increased over baseline	No
2	Increased over baseline	Yes
3	Minimal or no white blood cells	No
4	Minimal or no white blood cells	Yes

A: Platelets >5× baseline.

B: Platelets <5× baseline.

ACP is leucocyte poor (LP) and RBC depleted (a type 3b PRP), whereas PEAK is leucocyte rich (LR) and contains RBCs (a type 1a PRP).⁵ The objectives of this study were (1) to evaluate the cellular components of platelet concentrates produced by a LR-PRP system and a LP-PRP system, (2) to assess platelet growth factor release following reactivation of those platelet concentrates with CaCl₂, and (3) to evaluate the ability of those platelet concentrates to stimulate proliferation of tendon cells in vitro. Comparative evaluation studies of this nature are important for the advancement of the PRP field because evidence in the literature suggests that therapeutic success of PRP may vary based on the preparation method and PRP composition.^{5 10 13} Thus, there is a clear need to identify components that contribute to an ideal formulation that optimises the biological potential of platelet concentrates, including the reliability of the device to generate a reproducible platelet concentrate.

Methods

Study design

This study evaluates the cellular characteristics and reproducibility of platelet concentrates generated by an LR-PRP system (type 1a) and a LP-PRP system (type 3b). Parameters evaluated were platelet recovery, platelet concentration, RBC and WBC composition, platelet growth factor release following reactivation with CaCl₂ and the capacity of the releasate to stimulate human tendon cell proliferation in vitro.

Generation of platelet concentrates and haematology measurements

Whole fresh human blood anticoagulated with 12% anticoagulant citrate dextrose solution A (ACD-A) was obtained from Research Blood Components, LLC (Brighton, Massachusetts, USA). Platelet concentrates from the LR-PRP and LP-PRP systems were prepared in parallel for each donor according to the Instructions for Use contained in the device packaging. PRP was collected immediately following preparation and an aliquot for haematology analysis was diluted 1:3 with sterile phosphate buffered saline (PBS) containing 10 mM EDTA to ensure that platelet counts would fall within the calibrated linear range of detection (40 000–700 000 platelets/μL) for the Horiba ABX Micros 60 haematology analyser. Each sample was read three times and the mean haematology values were reported for each donor.

Serum generation

A total of 3 mL of ACD-A anticoagulated whole blood, LP-PRP, LR-PRP or platelet-poor plasma (PPP) was measured by graduated pipette and placed into sterile polypropylene tubes. Samples were reactivated physiologically with a final concentration of 25 mM calcium chloride to counteract the ACD-A anticoagulant for 80 min at room temperature. Serum samples were then prepared by centrifugation at 1000g for 10 min to pellet fibrin clots, and the fluid portion (serum) was collected into fresh sterile polypropylene tubes. The serum samples were centrifuged again at 1000g for 10 min to remove residual cells and debris. The cleared serum was aliquoted into Nalgene cryovials and frozen at -80°C until assayed for growth factor content and the capacity to stimulate tendon cell proliferation *in vitro*. For forced PRP activation, 100 units of bovine thrombin were added in addition with 25 mM CaCl_2 . Samples were immediately inverted several times to ensure mixing, and were incubated at room temperature for 60 min to allow complete coagulation. Serum samples were prepared as described above. No serum aliquots were freeze-thawed more than once prior to use in any assay.

Tendon cell proliferation studies

Normal healthy primary human patellar tendon fibroblasts (tenocytes) were purchased from Articular Engineering, LLC (Northbrook, Illinois) at passage #1. Cultures were expanded to passage #6 to ensure homogenous cell populations and appropriate acclimation to *in vitro* culture conditions. Cells were maintained at 37°C under 5% CO_2 in Dulbecco's-Modified Eagle Medium-F12 (DMEM-F12) supplemented with 10% fetal bovine serum (FBS), 1 \times antibiotic/antimycotic and 2 mM L-glutamine. For studies, cells were seeded into tissue culture-treated black-walled clear bottom 96-well plates at 1×10^3 cells/well in 100 μL volume. Cultures were washed once with 100 μL of DMEM-F12 24 h after seeding and synchronised for 24 h by serum restriction to 1% FBS. Eight wells per condition were treated in parallel (quadruplicate wells on duplicate plates) with serum derived from whole blood (positive control), PPP (negative control) or platelet concentrates from LP-PRP or LR-PRP. All serum dilutions were prepared in DMEM-F12 supplemented with 1 \times antibiotic/antimycotic, 2 mM L-glutamine and 0.25% FBS to maintain viability of the 0% serum-treated cultures. Cultures were incubated at 37°C under 5% CO_2 for 4 days. Wells were washed 1 \times with PBS to remove residual media, and relative proliferation was determined by CellTiter-Glo assay using a Molecular Diagnostics Spectramax M5 plate reader to measure luminescence.

Growth factor measurements

ELISA assay kits (Quantikine, R&D systems) were used to analyse the serum levels of five representative platelet growth factors (epidermal growth factor (EGF), transforming growth factor $\beta 1$ (TGF- $\beta 1$), platelet-derived growth factor AB (PDGF-AB), vascular endothelial growth factor (VEGF) and stromal-derived factor 1 α (SDF-1 α)). PPP that was prepared in parallel for each donor served as a negative control. Samples were assayed in duplicate and assay results were considered valid when r^2 values for the standard curves were greater than 0.99 and sample detection was within the linear range of the standard curve. Samples not within the linear detection range were diluted accordingly and reassayed.

Statistical analyses

Comparisons between groups were conducted using paired one-tailed Student t test, or by one-way analysis of variance (ANOVA) where indicated. Differences were considered significant when $p < 0.05$. The coefficient of variation, a ratio of the SD to the mean expressed as a per cent ($\% \text{CV} = (\text{SD}/\text{mean}) \times 100$), was also assessed for platelet recovery where a lower coefficient of variation (CV) indicates less variability.

Results

Platelet composition

The mean whole blood platelet count was $224 \times 10^3/\mu\text{L}$ ([table 2](#)). Each system significantly increased the platelet count compared with baseline levels ($p < 0.001$). LR-PRP demonstrated significantly greater increases in platelet concentration over baseline (7.9-fold) than LP-PRP (2.2-fold increase; $p < 0.001$) ([figure 1](#) and [table 2](#)). In addition, LP-PRP contained just over 50% of the total available platelets, while LR-PRP contained almost 90% ([figure 2](#) and [table 2](#)). LR-PRP demonstrated a greater reproducibility in platelet recovery with a 4.2% CV compared with a 19.4% CV for LP-PRP ($p < 0.001$) ([table 2](#)).

Table 2 Platelet parameters

	Mean platelet count ($\times 10^3/\mu\text{L}$)	Per cent recovery	Fold increase	Coefficient of variation (%)	p Value
Whole blood	224.2	NA	1.0	NA	<0.001
LP-PRP	485.9	52	2.2	19.4	<0.001
LR-PRP	1772.7	89	7.9	4.2	NA
PPP	8.6	NA	0.0	NA	NA

LP-PRP, leucocyte-poor platelet-rich plasma system; LR-PRP, leucocyte-rich platelet-rich plasma system; NA, not applicable; PPP, platelet-poor plasma.




Figure 1 Fold change in platelet concentration. Bars represent the mean \pm SD of the fold increase in platelet content (n=12 donors). Fold increase=platelet count in platelet concentrate/whole blood platelet count.




Figure 2

Platelet recovery. Bars represent the mean \pm SD of the percentage of total platelets recovered in platelet concentrates (n=12 donors). Per cent platelet recovery=(total platelet count of platelet concentrate (concentration \times total volume)/total platelet count of whole blood (concentration \times total volume)) \times 100.

RBC composition

The mean whole blood baseline RBC count was $4.04 \times 10^6/\mu\text{L}$, resulting in a mean haematocrit of 32.9 (table 3). Each of the systems reduced RBCs compared with whole blood. Haematocrit levels for LP-PRP and LR-PRP were 0.25 and 11.8, respectively ($p < 0.01$) (table 3).

Table 3

Red blood cell parameters

	Mean RBC count ($\times 10^6/\mu\text{L}$)	Per cent depletion	Coefficient of variation (%)	Fold change	Haematocrit
Whole blood	4.04	NA	NA	1.00	32.9
LP-PRP	0.05	99.8	0.31	0.01	0.25
LR-PRP	1.50	96.8	1.04	0.37	11.8
PPP	0.00	100.0	NA	NA	0

LP-PRP, leucocyte-poor platelet-rich plasma system; LR-PRP, leucocyte-rich platelet-rich plasma system; NA, not applicable; PPP, platelet-poor plasma; RBC, red blood cell.

WBC composition

The mean whole blood WBC count was $4.9 \times 10^3/\mu\text{L}$ (table 4). WBCs were reduced by fivefold in LP-PRP ($p < 0.001$), whereas LR-PRP showed a 4.0-fold increase in WBCs ($p < 0.001$) (table 4). LP-PRP contained just below 5% of the total available WBCs, while LR-PRP contained approximately 45% (table 4).

Table 4

White blood cell parameters

	Mean WBC count (\times $10^3/\mu\text{L}$)	Per cent recovery	Mean fold increase	Coefficient of variation (%)	Mean platelet:WBC ratio	p Value (2-tailed paired t test) vs LR-PRP system
Whole blood	4.9	100.0	1.0	NA	46	<0.001
LP-PRP	1.0	4.1	0.2	100	486	<0.001
LR- PRP	19.3	44.9	4.0	26	92	NA
PPP	0.0	0.0	NA	NA	NA	NA

LP-PRP, leucocyte-poor platelet-rich plasma system; LR-PRP, leucocyte-rich platelet-rich plasma system; NA, not applicable; PPP, platelet-poor plasma; WBC, white blood cells.

Tendon cell proliferation

Human tendon fibroblast cells were grown in vitro and exposed to varying concentrations of serum derived from either whole blood, PPP or platelet concentrates generated by LP-PRP or LR-PRP. Untreated cultures gave a very consistent baseline measurement with an across group mean of 209 ± 5 luminescence units, demonstrating excellent interassay and intra-assay repeatability and a common assay start point with respect to cell number per well ($p > 0.98$ by one-way ANOVA) (table 5). PPP stimulated a linear concentration-dependent proliferative response in human tenocytes ($r^2=1$) (table 5). Thus, to specifically compare the effects of platelet-derived growth factors on tendon cell proliferation, cell responses to serum were normalised to the PPP response and expressed as per cent (%) stimulation over PPP (figure 3).

Table 5

Tenocyte proliferation measurement (light units \pm SEM)

Serum concentration	0%	1%	2.5%	5%	10%
Whole blood	208 (29)	271 (19)	515 (46)	1087 (139)	2622 (95)
LP-PRP	214 (19)	281 (19)	554 (62)	1240 (134)	2656 (92)
LR-PRP	203 (17)	384 (46)	1001 (91)	2517 (180)	4372 (481)
PPP	210 (16)	269 (10)	370 (11)	530 (23)	795 (58)

LP-PRP, leucocyte-poor platelet-rich plasma system; LR-PRP, leucocyte-rich platelet-rich plasma system; PPP, platelet-poor plasma.




Figure 3 Stimulation of tendon cell proliferation. Data represent the mean \pm SD of preparations from five individual donors. All preparations from each donor were assayed in parallel using reactivated platelet-poor plasma as the baseline control for each serum concentration tested.

Serum from whole blood, LP-PRP and LR-PRP each stimulated a concentration-dependent proliferative response from tendon cells ([figure 3](#)). In fact, although the LP-PRP system preparations contained a 2.2-fold increase in platelets over whole blood ([figure 1](#)), the serum derived from those platelets did not evoke an enhanced proliferation response compared with whole blood ($p > 0.7$ by one-way ANOVA; [figure 3](#)). These results strongly suggest that the LP-PRP system preparations are deficient in platelet activation and growth factor release. In contrast, LR-PRP stimulated a proliferation dose-response that was significantly greater than that of either LP-PRP or whole blood ($p < 0.05$ for each by one-way ANOVA; [figure 3](#) and [table 5](#)). More specifically, the serum from LR-PRP at a concentration of 10% (volume:volume) in the culture medium stimulated robust proliferation that was sufficient to cause the cultures to grow to confluence, saturating the assay system. This finding is important because normal somatic cells such as the tendon fibroblasts used in these studies exhibit contact-dependent inhibition of proliferation when grown in culture, whereby cells that are surrounded by other cells can no longer respond to serum growth signals.³⁰ This effect is evidenced by the apparent flattening of the slope of the serum response curve between 5% and 10% serum for LR-PRP ([figure 3](#)).

Growth factor analysis

Whole blood and LR-PRP achieved a robust activation of the coagulation cascade following reactivation with CaCl_2 , including strong clot retraction. In contrast, LP-PRP and PPP displayed donor-dependent irregularity in the robustness and degree of clotting, and none of the LP-PRP or PPP clots demonstrated retraction to the extent of whole blood (data not shown). This indicates a deficiency in activation of the coagulation cascade and also in platelet function, since clot retraction is a platelet-driven process.³¹ Further consistent with a platelet functional deficiency in LP-PRP, a lower level of growth factors compared with whole blood serum was found despite that LP-PRP contained 2.2-fold more platelets ([figures 1](#) and [and44](#) and [table 6](#)). In fact, the levels of EGF and TGF- $\beta 1$ were significantly lower in the LP-PRP serum compared with whole blood ($p < 0.03$ for both; [figure 4](#) and [table 6](#)). In contrast, LR-PRP demonstrated significantly higher growth factor levels with serum from whole blood ($p < 0.01$ for each; [figure 4](#) and [table 6](#)).

Table 6

Serum growth factor levels (pg/mL) following reactivation with CaCl_2

Platelet growth factor	Whole blood	LP-PRP system	LR-PRP system	PPP
EGF	2880	2350	12 475	130
TGF-β1	4820	3908	19 992	236
PDGF-AB	35 580	29 140	158 480	1160
VEGF	269.6	264.4	1381.6	19.2
SDF-1α	4975	4755	9530	3840

EGF, epidermal growth factor; LP-PRP, leucocyte-poor platelet-rich plasma system; LR-PRP, leucocyte-rich platelet-rich plasma system; PDGF-AB, platelet-derived growth factor AB; PPP, platelet-poor plasma; SDF-1α, stromal-derived factor 1α; TGF-β1, transforming growth factor β1; VEGF, vascular endothelial growth factor.




Figure 4

Serum growth factor release. Platelet-poor plasma, whole blood and platelet concentrates from the LP-PRP and LR-PRP systems were reactivated with a final concentration of 25 mM CaCl₂ for 80 min at room temperature. Growth factor levels were measured in the resulting serum by ELISA. Bars represent the mean ± SD from five independent donors. All preparations from each donor were assayed in parallel. LP-PRP, leucocyte-poor platelet-rich plasma; LR-PRP, leucocyte-rich platelet-rich plasma.

The failure of LP-PRP to demonstrate robust coagulation and platelet growth factor release in response to reactivation with CaCl₂ suggested that LP-PRP may be deficient in thrombin generation under physiological conditions. To test this, LP-PRP was directly activated with 100 units of bovine thrombin in addition to 25 mM CaCl₂, and growth factor measurements were conducted on the serum samples. Robust coagulation was induced in each sample within seconds of the addition of thrombin, indicating that exogenous thrombin can indeed rescue the clotting deficiency observed for LP-PRP. Forced activation with exogenous thrombin also improved platelet growth factor release in LP-PRP compared with activation with CaCl₂ alone, respective to whole blood controls (figure 5). Taken together, these data indicate that LP-PRP preparations are deficient in thrombin generation on reactivation with CaCl₂.




Figure 5

Growth factor release from LP-PRP system preparations. Bars represent the mean \pm SD of the fold change in serum growth factor content of LP-PRP activated with CaCl_2 (blue bars; n=5 donors) or exogenously with CaCl_2 + thrombin (red bars; n=7 donors). * $p < 0.03$ compared with whole blood. ** $p < 0.01$ compared with whole blood. The green line represents whole blood platelet growth factor levels (set to 1-fold for comparison). LP-PRP, leucocyte-poor platelet-rich plasma.

Discussion

Evidence in the literature suggests that clinical success of PRPs may vary based on the preparation method and PRP composition.^{9 13 32} Thus, there is a need to evaluate PRP formulations to discern the role of non-platelet cellular components in determining the potential efficacy of PRP generated by different systems. The primary objectives of the current study were to characterise the cellular components of LR-PRP (a type 1a PRP containing RBCs) and LP-PRP (a type 3b PRP, ie, RBC depleted) and to examine the contributions that RBCs and WBCs collectively have on platelet growth factor release and the efficacy of the releasate to stimulate tendon cell proliferation in vitro. LR-PRP contained almost 90% of the available platelets, resulting in approximately 7.9-fold increase over whole blood with a 4.2% coefficient of variation, which indicates a high degree of reproducibility in platelet concentration. WBCs were concentrated approximately four-fold over whole blood in LR-PRP, which was sufficient to maintain platelet to WBC ratios within a physiological range for each donor tested. The platelet to WBC ratio is a metric that has recently gained attention as a parameter that may be important for the anabolic activity of PRP,^{14 33} although the influence of this ratio on PRP bioactivity remains controversial. LR-PRP RBC levels were reduced to a haematocrit of 11.8, almost threefold lower than whole blood. The LR-PRP was type 1A, and demonstrated robust physiological responsiveness to reactivation with CaCl_2 . Complete coagulation with robust clot retraction was seen with LR-PRP, and this was evidenced by high serum growth factor content (table 6 and figure 4) and strong stimulation of tendon cell proliferation in vitro (table 5 and figure 3). Indeed, tendon cells stimulated with 10% serum from LR-PRP saturated the growth surface of the cell culture dishes, thus reaching the plateau for proliferation in vitro. Overall, these results indicate excellent platelet viability in the LR-PRP and suggest that robust platelet activity should be expected in a physiological setting.

The LP-PRP had a mean platelet increase of 2.2-fold over whole blood and mean platelet recoveries of 52% with a coefficient of variation of 19.4%, indicating a high degree of variability. LP-PRP had WBCs reduced fivefold compared with whole blood. RBCs were reduced 100-fold, to a haematocrit of 0.25. Platelet function in the LP-PRP was deficient, as evidenced by a failure to consistently coagulate and undergo clot retraction when reactivated with CaCl_2 alone. Consistent with this, serum from LP-PRP did not demonstrate elevated growth factor levels (figure 4), and the stimulation of tendon cell proliferation was not significantly different than serum from whole blood (figure 3). This deficiency in platelet activation was at least in part attributable to a failure of

the LP-PRP to generate sufficient thrombin because addition of exogenous thrombin rescued the coagulation deficit and improved platelet growth factor release (figure 5).

Recently published studies have demonstrated that the intimate interactions between platelets and other blood cells are crucial for the physiological mechanisms to prevent infection and promote healing in the event of an injury, and that the failure of these mechanisms can promote pathological tissue states that contribute to disease.^{8 11 17-25 34-37} The current study further contributes to this body of evidence, in that it uncovers a deficiency in platelet function with respect to growth factor release and the ability of the releasate to stimulate tendon cell proliferation when RBCs and leucocytes are lacking. A limitation of this study is that a detailed analysis of tendon cell viability was not conducted. Therefore, although the CellTiter-Glo assay that was used to determine cell proliferation measures the production of ATP specifically from viable cells, the relative contribution from prevention of apoptotic cell death and/or cellular senescence remains to be determined. In addition, it is well established that exposure of tendon fibroblasts to high levels of TGF- β 1 in vitro can activate their trans-differentiation to myofibroblasts (review by Hinz³⁸). Myofibroblasts play an integral role in wound healing reactions due to their induced expression of smooth muscle actin that results in an acquired ability to contract and to contribute to physiological tissue repair.³⁸ Myofibroblast contraction also leads to the liberation of TGF- β 1 from these cells,³⁸ leading to the potential of a feed-forward mechanism to promote further fibroblast trans-differentiation. Further research will be required to determine the extent to which LR-PRP promotes fibroblast trans-differentiation, as this may represent an important mechanism through which PRP therapy may provide clinical benefit. Another important limitation of this study is that it is an in vitro study comparing two polar opposite platelet concentrate formulations (type 1a and type 3b).⁵ Therefore, the conclusions remain to be validated in animal models or the clinical setting. Further studies will be required to elucidate the precise individual contributions of platelets, RBCs and WBCs to the beneficial effects of PRP that are emerging in the scientific literature for various clinical applications.^{3-5 7}

Conclusion

LP-PRP did not demonstrate robust coagulation and platelet growth factor release compared with whole blood and LR-PRP. In addition, serum derived from LP-PRP did not provide a significant advantage to tendon cell proliferation compared with whole blood serum, although the LP-PRP contained a 2.2-fold increase in platelet concentration. These findings suggest that the non-platelet cellular components that are excluded from the LP-PRP are important for optimal platelet function, including thrombin generation leading to robust coagulation, growth factor release and the resulting capacity of the serum to stimulate cell proliferation. Future studies should be conducted to validate these findings in vivo, as these findings may have profound implications for how platelet concentrates are prepared and utilised in clinical applications.

Footnotes

Contributors: WRP, BR, JH and BS conceived and designed the experiments. WRP analysed the data. WRP and BR wrote the first draft of the manuscript. WRP, MM and SB contributed to the writing of the manuscript. WRP, BR, JH, SB, MM and BS agree with manuscript results and conclusions. WRP, BR, SB and MM jointly developed the structure and arguments for the paper. WRP, BR, JH, BS, MM and SB made critical revisions and approved final version. All authors reviewed and approved of the final manuscript.

Funding: Support for this research was provided by DePuy Synthes Mitek Sports Medicine, Raynham, Massachusetts, USA.

Competing interests: WRP, BR, JH, SB and BS are employees of DePuy Synthes Mitek Sports Medicine, a Johnson & Johnson Company. MM is a paid consultant for DePuy Synthes Mitek Sports Medicine and an employee of Health Economics Associates, LLC.

Provenance and peer review: Not commissioned; externally peer reviewed.

References

1. Marx RE. Platelet-rich plasma: evidence to support its use. *J Oral Maxillofac Surg* 2004;62:489–96. [doi:10.1016/j.joms.2003.12.003](https://doi.org/10.1016/j.joms.2003.12.003) [PubMed]
2. Anitua E, Andia I, Ardanza B et al. Autologous platelets as a source of proteins for healing and tissue regeneration. *Thromb Haemost* 2004;91:4–15. [doi:10.1160/TH03-07-0440](https://doi.org/10.1160/TH03-07-0440) [PubMed]
3. Hall MP, Band PA, Meislin RJ et al. Platelet-rich plasma: current concepts and application in sports medicine. *J Am Acad Orthop Surg* 2009;17:602–8. [PubMed]
4. Sampson S, Gerhardt M, Mandelbaum B. Platelet rich plasma injection grafts for musculoskeletal injuries: a review. *Curr Rev Musculoskelet Med* 2008;1:165–74. [doi:10.1007/s12178-008-9032-5](https://doi.org/10.1007/s12178-008-9032-5)[PMC free article] [PubMed]
5. Mishra A, Harmon K, Woodall J et al. Sports medicine applications of platelet rich plasma. *Curr Pharm Biotechnol* 2012;13:1185–95. [doi:10.2174/138920112800624283](https://doi.org/10.2174/138920112800624283) [PubMed]
6. Ahmad Z, Howard D, Brooks RA et al. The role of platelet rich plasma in musculoskeletal science. *JRSM Short Rep* 2012;3:40 [doi:10.1258/shorts.2011.011148](https://doi.org/10.1258/shorts.2011.011148) [PMC free article] [PubMed]
7. Halpern BC, Chaudhury S, Rodeo SA. The role of platelet-rich plasma in inducing musculoskeletal tissue healing. *HSS J* 2012;8:137–45. [doi:10.1007/s11420-011-9239-7](https://doi.org/10.1007/s11420-011-9239-7) [PMC free article] [PubMed]
8. Bielecki T, Dohan Ehrenfest DM, Everts PA et al. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. *Curr Pharm Biotechnol* 2012;13:1153–62. [doi:10.2174/138920112800624373](https://doi.org/10.2174/138920112800624373) [PubMed]
9. Chang KV, Hung CY, Aliwarga F et al. Comparative effectiveness of platelet-rich plasma injections for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. *Arch Phys Med Rehabil* 2014;95:562–75. [doi:10.1016/j.apmr.2013.11.006](https://doi.org/10.1016/j.apmr.2013.11.006) [PubMed]
10. Dohan Ehrenfest DM, Bielecki T, Jimbo R et al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). *Curr Pharm Biotechnol* 2012;13:1145–52. [doi:10.2174/138920112800624382](https://doi.org/10.2174/138920112800624382) [PubMed]
11. Elstad MR, McIntyre TM, Prescott SM et al. The interaction of leukocytes with platelets in blood coagulation. *Curr Opin Hematol* 1995;2:47–54. [doi:10.1097/00062752-199502010-00007](https://doi.org/10.1097/00062752-199502010-00007) [PubMed]
12. Santos MT, Valles J, Aznar J et al. Role of red blood cells in the early stages of platelet activation by collagen. *Thromb Haemost* 1986;56:376–81. [PubMed]
13. Riboh JC, Saltzman BM, Yanke AB et al. Effect of leukocyte concentration on the efficacy of platelet-rich plasma in the treatment of knee osteoarthritis. *Am J Sports Med* 2015.[doi:10.1177/0363546515580787](https://doi.org/10.1177/0363546515580787) [PubMed]
14. McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. *J Bone Joint Surg Am* 2012;94:e143–8. [doi:10.2106/JBJS.L.00019](https://doi.org/10.2106/JBJS.L.00019)[PubMed]
15. Braun HJ, Kim HJ, Chu CR et al. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. *Am J Sports Med* 2014;42:1204–10. [doi:10.1177/0363546514525593](https://doi.org/10.1177/0363546514525593) [PMC free article] [PubMed]
16. Drago JL, Braun HJ, Durham JL et al. Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. *Am J Sports Med* 2012;40:1274–81. [doi:10.1177/0363546512442334](https://doi.org/10.1177/0363546512442334) [PubMed]
17. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. *Nat Rev Immunol* 2011;11:264–74. [doi:10.1038/nri2956](https://doi.org/10.1038/nri2956) [PubMed]
18. Valles J, Santos MT, Aznar J et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. *Blood* 1991;78:154–62. [PubMed]
19. Valles J, Santos MT, Aznar J et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. *Blood* 2002;99:3978–84. [doi:10.1182/blood.V99.11.3978](https://doi.org/10.1182/blood.V99.11.3978) [PubMed]

20. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. *FASEB J* 1993;7:516–22. [[PubMed](#)]
21. Broos K, Feys HB, De Meyer SF et al. Platelets at work in primary hemostasis. *Blood Rev* 2011;25:155–67. [doi:10.1016/j.blre.2011.03.002](#) [[PubMed](#)]
22. Cerletti C, de Gaetano G, Lorenzet R. Platelet—leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk. *Mediterr J Hematol Infect Dis* 2010;2:e2010023 [doi:10.4084/MJHID.2010.023](#) [[PMC free article](#)] [[PubMed](#)]
23. Del Maschio A, Dejana E, Bazzoni G. Bidirectional modulation of platelet and polymorphonuclear leukocyte activities. *Ann Hematol* 1993;67:23–31. [doi:10.1007/BF01709662](#) [[PubMed](#)]
24. Ghasemzadeh M, Hosseini E. Platelet-leukocyte crosstalk: linking proinflammatory responses to procoagulant state. *Thromb Res* 2013;131:191–7. [doi:10.1016/j.thromres.2012.11.028](#) [[PubMed](#)]
25. Jenne CN, Urrutia R, Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. *Int J Lab Hematol* 2013;35:254–61. [doi:10.1111/ijlh.12084](#) [[PubMed](#)]
26. Versteeg HH, Heemskerk JW, Levi M et al. New fundamentals in hemostasis. *Physiol Rev* 2013;93:327–58. [doi:10.1152/physrev.00016.2011](#) [[PubMed](#)]
27. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. *Trends Immunol* 2004;25:489–95. [doi:10.1016/j.it.2004.07.003](#) [[PubMed](#)]
28. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. *Blood Rev* 2007;21:99–111. [doi:10.1016/j.blre.2006.06.001](#) [[PubMed](#)]
29. Enoch S, Leaper DJ. Basic science of wound healing. *Surgery (Oxford)* 2005;23:37–42. [doi:10.1383/surg.23.2.37.60352](#)
30. McClatchey AI, Yap AS. Contact inhibition (of proliferation) redux. *Curr Opin Cell Biol* 2012;24:685–94. [doi:10.1016/j.ceb.2012.06.009](#) [[PubMed](#)]
31. de Witt SM, Verdoold R, Cosemans JM et al. Insights into platelet-based control of coagulation. *Thromb Res* 2014;133:S139–48. [doi:10.1016/S0049-3848\(14\)50024-2](#) [[PubMed](#)]
32. Boswell SG, Cole BJ, Sundman EA et al. Platelet-rich plasma: a milieu of bioactive factors. *Arthroscopy* 2012;28:429–39. [doi:10.1016/j.arthro.2011.10.018](#) [[PubMed](#)]
33. Boswell SG, Schnabel LV, Mohammed HO et al. Increasing platelet concentrations in leukocyte-reduced platelet-rich plasma decrease collagen gene synthesis in tendons. *Am J Sports Med.* 2014;42:42–9. [doi:10.1177/0363546513507566](#) [[PubMed](#)]
34. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. *Blood Rev* 2009;23:177–89. [doi:10.1016/j.blre.2009.04.001](#) [[PMC free article](#)] [[PubMed](#)]
35. Cerletti C, Evangelista V, De Gaetano G. Polymorphonuclear leukocyte-dependent modulation of platelet function: relevance to the pathogenesis of thrombosis. *Pharmacol Res* 1992;26:261–8. [doi:10.1016/1043-6618\(92\)90213-U](#) [[PubMed](#)]
36. Marcus AJ. Neutrophils inhibit platelet reactivity by multiple mechanisms: relevance to thromboregulation. *J Lab Clin Med* 1990;116:138–9. [[PubMed](#)]
37. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. *Platelets* 2001;12:261–73. [doi:10.1080/09537100120068170](#) [[PubMed](#)]
38. Hinz B. Formation and function of the myofibroblast during tissue repair. *J Invest Dermatol* 2007;127:526–37. [doi:10.1038/sj.jid.5700613](#) [[PubMed](#)]